<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02183493</url>
  </required_header>
  <id_info>
    <org_study_id>1218.34</org_study_id>
    <nct_id>NCT02183493</nct_id>
  </id_info>
  <brief_title>Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female Subjects</brief_title>
  <official_title>Relative Bioavailability of a 5 mg BI 1356 Tablet Administered With and Without Food to Healthy Male and Female Subjects in an Open, Randomised, Single Dose, Two-way Crossover, Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate the food effect on the relative bioavailability and pharmacokinetics of a 5 mg
      BI 1356 tablet administered as a single dose
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of BI 1356 in plasma over the time interval from 0 to 72 h (AUC0-72)</measure>
    <time_frame>up to 72 hours after start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration (Cmax) of BI 1356 in plasma</measure>
    <time_frame>up to 96 hours after start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of BI 1356 in plasma at different time points</measure>
    <time_frame>up to 96 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum concentration (tmax) of BI 1356 in plasma</measure>
    <time_frame>up to 96 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (λz) in plasma</measure>
    <time_frame>up to 96 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of BI 1356 in plasma</measure>
    <time_frame>up to 96 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time of BI 1356 in the body after oral administration (MRTpo)</measure>
    <time_frame>up to 96 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of BI 1356 in the plasma after extravascular administration (CL/F)</measure>
    <time_frame>up to 96 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)</measure>
    <time_frame>up to 96 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability on a 4-point scale by investigator</measure>
    <time_frame>14 days after last study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fed administration of BI 1356</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fasted administration of BI 1356</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1356</intervention_name>
    <arm_group_label>Fed administration of BI 1356</arm_group_label>
    <arm_group_label>Fasted administration of BI 1356</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females according to the following criteria:

             -- Based upon a complete medical history, including the physical examination, vital
             signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG),
             clinical laboratory tests

          -  Age ≥ 18 and Age ≤ 50 years

          -  BMI ≥ 18.5 and BMI ≤ 29.9 kg/m2 (Body Mass Index)

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with good clinical practice (GCP) and the local legislation

        Exclusion Criteria:

          -  Any finding of the medical examination deviating from normal and of clinical
             relevance. Repeated measurement of a systolic blood pressure greater than 140 mm Hg or
             diastolic blood pressure greater than 90 mm Hg

          -  Any evidence of a clinically relevant concomitant disease

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Surgery of the gastrointestinal tract (except appendectomy)

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  History of relevant orthostatic hypotension, fainting spells or blackouts

          -  Chronic or relevant acute infections

          -  History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          -  Intake of drugs within one month or less than 10 half-lives of the respective drug
             prior to first study drug administration and during the trial except if a relevant
             interaction can be ruled out

          -  Participation in another trial with an investigational drug within two months prior to
             first study drug administration or during the trial

          -  Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)

          -  Inability to refrain from smoking on trial days

          -  Alcohol abuse (average consumption of more than 20 g/day in females and 30 g/day in
             males)

          -  Drug abuse

          -  Blood donation (more than 100 mL within four weeks prior to the start of study)

          -  Excessive physical activities (within one week prior to administration or during the
             trial)

          -  Any laboratory value outside the reference range that is of clinical relevance

          -  Inability to comply with dietary regimen of trial site

          -  A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTc interval &gt;450 ms)

          -  A history of additional risk factors for torsades de points (e.g., heart failure,
             hypokalemia, family history of Long QT Syndrome)

        For female subjects:

          -  Positive pregnancy test, pregnancy or planning to become pregnant during the study or
             within 2 months after study completion

          -  No adequate contraception during the study and until 2 months after study completion,
             i.e. not any of the following: implants, injectables, combined oral contraceptives,
             intrauterine device (IUD) , sexual abstinence for at least 1 month prior to enrolment,
             vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or
             surgical sterilisation (including hysterectomy). Females, who do not have a
             vasectomised partner, are not sexually abstinent or surgically sterile will be asked
             to use an additional barrier method (e.g. condom, diaphragm with spermicide)

          -  Lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 4, 2014</last_update_submitted>
  <last_update_submitted_qc>July 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

